Small Cell Lung Cancer News

News

First-Line Atezolizumab Plus Chemotherapy Not Cost-Effective for SCLC

06/23/2021

A recent cost-effective analysis of first-line treatments for extensive-stage SCLC suggests that atezolizumab plus chemotherapy is not cost-effective in the United States.

A recent cost-effective analysis...

06/23/2021

Journal of Clinical Pathways

News

Cost-Effectiveness of Prophylactic Cranial Irradiation vs MRI Surveillance for Small Cell Lung Cancer

06/18/2021

A recent study revealed that prophylactic cranial irradiation is not cost-effective compared with MRI surveillance for extensive-stage small cell lung cancer.

A recent study revealed that...

06/18/2021

Journal of Clinical Pathways

News

Platinum-Doublet Chemo Shows Efficacy as a Second-Line Treatment for Relapsed SCLC

05/06/2021

For patients with relapsed SCLC, second-line, platinum-doublet chemotherapy may be beneficial over non-platinum regimens.

For patients with relapsed SCLC,...

05/06/2021

Oncology

News

PD-L1 Inhibitor Plus Etoposide-Platinum Regimen Promising for Extensive-Stage SCLC

11/11/2020

Results from a systematic review show that a PD-L1 inhibitor plus etoposide-based chemotherapy could be an optimal first-line treatment for ES-SCLC.

Results from a systematic review...

11/11/2020

Oncology

News

Basics of Immunotherapy in SCLC

10/03/2020

In a session presented at the 2020 Personalized Therapies in Thoracic Oncology virtual meeting, Stephen V. Liu, MD, Georgetown Lombardi Comprehensive Cancer Center, Washington, D.C, shared insight on immunotherapy treatment for SCLC.

In a session presented at the...

10/03/2020

Oncology

News

No Survival Advantage With Whole-Brain RT vs Stereotactic Radiosurgery for SCLC

08/24/2020

In patients with SCLC, whole-brain RT yielded a superior time to central nervous system progression but no advantage in survival compared with stereotactic radiosurgery.

In patients with SCLC,...

08/24/2020

Oncology

News

First-Line Pembrolizumab Combo Improves PFS in Patients With Extensive-Stage SCLC

06/22/2020

First-line therapy with pembrolizumab plus etoposide and platinum (EP) led to significantly improved PFS compared with placebo plus EP in patients with ES-SCLC.

First-line therapy with...

06/22/2020

Oncology

News

FDA Approves Lurbinectedin for Adults With Metastatic SCLC

06/15/2020

The FDA has approved lurbinectedin for the treatment of adults with metastatic SCLC that progressed during or after platinum-based chemotherapy.

The FDA has approved...

06/15/2020

Oncology

News

Second-Line Lurbinectedin Shows Activity, Acceptable Safety in SCLC

05/12/2020

In a phase 2 study of patients with SCLC, second-line lurbinectedin was active and yielded a manageable safety profile.

In a phase 2 study of patients...

05/12/2020

Oncology

News

FDA Approves Durvalumab–Chemo Combo for Extensive-Stage SCLC

03/30/2020

The FDA has approved durvalumab plus etoposide and carboplatin or cisplatin for the first-line treatment of patients with extensive-stage SCLC.

The FDA has approved durvalumab...

03/30/2020

Oncology

Current Issue

October 2024

Volume 10

Issue 5

Current Issue

Issue Archive

Special Reports

Sponsored

JCP Special Report

The Value of Tissue-Based Genomic Profiling in Oncology

09/17/2024

Innovations in precision oncology have helped healthcare providers to create more personalized treatment plans and improve patient outcomes. View this special report to learn more.

Innovations in precision...

09/17/2024

Journal of Clinical Pathways

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee ;

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Robin T. Zon , MD, FACP, FASCO;

Gordon Kuntz ;

Winston Wong , PharmD;

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan ;

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Sponsored

Special Report

Navigating the Patient Journey for Unresectable Stage III Non-Small Cell Lung Cancer

09/16/2021

.ryan-test { display: none; } .body-content h3 { font-size: 18px; line-height: 18px; color: #000000; font-weight: 600px; } .related-content { display: none; } .body-content div > div:nth-of-type(3) .paragraph > h3 >...

.ryan-test { display:...

09/16/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Small Cell Lung Cancer News

Current Issue

Special Reports

Subscribe

Specialties

Events

Year Round Education

HMP Global Products